Background {#Sec1}
==========

Infection, in particular pneumonia, is an important cause of the excess mortality in patients with rheumatoid arthritis (RA) \[[@CR1]\] and recurrent pulmonary infections are reported in 10--35% of Sjögren's syndrome patients \[[@CR2]\]. Doran et al. found an 80% increased risk of infection in a retrospective cohort of RA patients, compared to age- and sex-matched subjects without RA \[[@CR3]\]. In addition, the authors reported that older age, presence of extra-articular manifestations, leukopenia, comorbid conditions (e.g. diabetes mellitus), and use of corticosteroids, but not traditional disease modifying anti-rheumatic drugs (DMARDs), were strong predictors of infection \[[@CR4]\]. More recently, a systematic review and meta-analysis by Singh et al. showed that in comparison to traditional DMARDs, standard-dose biological drugs and high-dose biological drugs were associated with an increased risk of serious infections, (Odds ratios 1.31 and 1.90, respectively) \[[@CR5]\].

Invasive pneumococcal disease (IPD), caused by *Streptococcus pneumoniae*, is a vaccine-preventable life-threatening condition. Retrospective cohort studies have demonstrated increased risks of IPD in patients with autoimmune inflammatory rheumatic diseases, i.e. RA (Rate ratio \[RR\] 2.47, 95% confidence interval \[CI\] 2.41--2.52) and primary Sjögren's syndrome (pSS) (RR 3.2, 95% CI 2.9--3.5) \[[@CR6]\].

Two pneumococcal vaccine types are currently available for adults, the 23-valent pneumococcal polysaccharide (PPV23) and the 13-valent conjugate vaccine (PCV13). The advantage with the conjugate vaccine is the T cell-dependent (TD) immune response, resulting in the production of memory B-cells. Our group have previously reported that antibody responses to PPV23 \[[@CR7]\] and 7-valent pneumococcal conjugate vaccine (PCV7) \[[@CR8]\] are impaired in chronic arthritis patients during treatment with methotrexate (MTX), but not with tumour necrosis factor (TNF) inhibitor monotherapy. The current recommendation for adults with immunocompromising conditions, is to receive immunization with a dose of PCV13, followed in at least 8 weeks by a dose of PPV23 \[[@CR9]\]. RA and pSS are systemic autoimmune inflammatory diseases, but little is known whether the immunological disturbance as a part of disease itself influences the immune response to PCV13 vaccination since studies of the vaccine response in untreated RA and pSS patients are scarse or non-existing. The aim of this study was to investigate if antibody response and functionality of antibodies following immunization with PCV13 is impaired in patients with RA and pSS without active anti-rheumatic treatment compared to RA patients treated with methotrexate (MTX), or to healthy controls.

Methods {#Sec2}
=======

Patient inclusion {#Sec3}
-----------------

Adult patients with RA and pSS, regularly monitored at the Department of Rheumatology in Lund and Malmö at Skåne University Hospital were eligible for this study. At inclusion in the present study all patients' medical records were scrutinised in order to confirm that patients fulfilled the American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) criteria for RA or pSS \[[@CR10], [@CR11]\]. Ongoing treatment at the time of vaccination was noted as a basis for later patient stratification. Patients were excluded from the study if anti-rheumatic treatment had been changed within 4 weeks before vaccination, if they had been previously vaccinated with PPV23 within 1 year, had a history of allergic reaction at previous vaccinations, were pregnant, or had an ongoing infection. Healthy control subjects were recruited from the staff and relatives at the department of Rheumatology in Lund. The controls were younger (median 57.2 years) than RA patients (median 66.9 years, *p* \< 0.001).

Ethics approval and consent to participate {#Sec4}
------------------------------------------

The study was approved by the Regional Ethical Review Board at Lund University, Sweden (Dnr 2011/341). Consecutive patients fulfilling inclusion criteria were invited to participate in the study. All invited participants were provided with oral and written information, and written consent was obtained before study enrolment.

Vaccination protocol {#Sec5}
--------------------

All participants received a single 0.5 mL dose of PCV13 (Prevenar 13®, Pfizer) administered as an intramuscular injection in the deltoid muscle. At the time of vaccination, a rheumatologist performed a clinical examination and data were collected on disease and treatment characteristics and previous vaccinations using a structured protocol. All participants were encouraged to report any adverse events following vaccination, as well as possible changes in rheumatic disease. Adverse events (AEs) and adverse drug reactions (ADRs) were recorded in line with the Guideline for Good Clinical Practice and Clinical Safety Data Management \[[@CR12]\].

Pneumococcal serotype-specific IgG measurement {#Sec6}
----------------------------------------------

Serum samples were collected immediately before and 4--6 weeks after vaccination. Serotype-specific IgG antibody concentrations for pneumococcal serotypes 6B and 23F, both included in PCV13, were quantified using enzyme-linked immunosorbent assay (ELISA). The World Health Organization consensus pneumococcal IgG ELISA \[[@CR13]\] was performed with minor modifications, described previously \[[@CR14]\].

Opsonophagocytic activity (OPA) assay {#Sec7}
-------------------------------------

Flow cytometric OPA assay was performed for pneumococcal serotype 23F. The original method has been described by *Martinez* et al. \[[@CR15]\] and it was executed with some modifications \[[@CR14]\].

Statistical analysis {#Sec8}
--------------------

Differences between groups were analysed using the Chi-square test and the Mann-Whitney U test when appropriate. Geometric mean Ab concentrations (GMCs) and 95% confidence intervals (95% CI) were calculated from log-transformed values. Pre- and post-PCV13 GMCs for larger groups (*n* \> 30) were compared using paired samples t-test. Pre- to postvaccine OPA and antibody changes in smaller groups were compared using Wilcoxon signed rank test. Differences in GMCs between patients (*n* \> 20) and controls were analysed using independent samples t-test. A positive antibody response was defined as an antibody response ratio (ARR, i.e., the ratio of post- to prevaccination antibody levels) ≥2. Putative protective level for each serotype was defined as a titer ≥1.3 μg/mL, as recommended by the American Academy of Allergy, Asthma & Immunology \[[@CR16]\]. Predictors of positive antibody response for both serotypes were analysed using logistic regression model, adjusted for age. Correlations between "% changes in OPA" and ELISA difference in each groups were calculated using Spearman's rank correlation test. Statistical calculations were performed using IBM® SPSS® version 23 and diagrams were drawn using Graphpad Prism® version 6.

Results {#Sec9}
=======

A total of 60 patients with RA (50 without DMARD and 10 on MTX), 15 patients with pSS without DMARD and 49 controls were vaccinated. None was lost to follow up. In the RA without DMARD group 58% were treated with prednisolone (median dose 5 mg daily, range 0--15 mg). The demographic details, disease characteristics, pre- and postvaccination geometric mean antibody concentrations of the participants are shown in Table [1](#Tab1){ref-type="table"}. Prevaccination GMCs neither differed significantly between the patient groups nor compared to controls. Pre- to postvaccination increases of serotypes 6B and 23F GMCs were found in patients with RA without DMARD (both *p* \< 0.001), pSS (*p* = 0.05 and *p* = 0.006) and controls (both *p* \< 0.001). The small patient group RA with MTX only showed increase in serotype 6B GMC (*p* = 0.05).Table 1Demographic and patient characteristics in treatment groups and controlsRA without DMARD\
(*n =* 50)RA with MTX\
(*n =* 10)pSS without DMARD (*n* = 15)Controls\
(*n =* 49)Age, median (range) years66.9 (35--87)67.4 (39--79)62.3 (25--89)57.2 (17--85)Sex (% female)78.070.087.063.3Disease duration, mean (range) years5.6 (0--36)13.1 (2--40)7.0 (0--23)--CRP, median (range) mg/L7 (0--78)3 (0--11)1.7 (0.7--38)--ESR, median (range) mm/h21 (4--71)16 (5--42)12 (7--66)--RF positive, %788043--ACPA positive, %69708--ANA positive, %----73--Anti-ENA positive, %----73--Anti-SSA (anti-Ro) positive, %----67--Anti-SSB (anti-La) positive, %----40--Prednisolone, %580130Dose, median (range) mg/day5 (0--15)00 (0--10)--Previous PPV23, *n* (%):1 (2)003 (6)*DMARD* Disease modifying anti rheumatic drugs, *RA* Rheumatoid arthritis, *pSS* primary Sjögren's syndrome, *CRP* C-reactive protein, *ESR* Erythrocyte sedimentation rate, *ACPA* Antibodies against citrullinated peptides, *ANA* Antinuclear antibodies, *Anti-ENA* Antibodies against extractable nuclear antigens, *Anti-SSA (anti-Ro)* Anti-Sjögren's-syndrome-related antigen A, *Anti-SSB (anti-La)* Anti-Sjögren's-syndrome-related antigen B, *RF* Rheumatoid factor

Antibody response {#Sec10}
-----------------

Proportions of subjects with a positive antibody response (i.e. antibody response ratio; ARR ≥ 2) to serotypes 6B and 23F was decreased in patients with RA on MTX treatment (both *p* \< 0.01), but not in RA without DMARD or pSS without DMARD, compared to controls (Fig. [1](#Fig1){ref-type="fig"}). Proportions of antibody responders to both serotypes did not differ significantly between groups RA without DMARD (52%), pSS without DMARD (40%) and controls (55%). When a logistic regression analysis was performed, RA on MTX was the only group with a significant lower positive antibody response to both serotypes. Due to limited number of patients in this group and patients with pSS only adjustment for age could be performed (Table [2](#Tab2){ref-type="table"}).Fig. 1Proportions of subjects with a positive antibody response PCV13 vaccinationTable 2Predictors of a positive antibody response (i.e. antibody response ratio; ARR ≥ 2) to both 6B and 23F*p*-valueOR95% CIRA without DMARD (yes/no)0.1611RA with MTX (yes/no)0.0370.100.01--0.87pSS without DMARDs (yes/no)0.3700.580.18--1.90Controls (yes/no)0.9920.990.42--2.39Age at vaccination (years)0.4960.990.97--1.02

Putative protective levels {#Sec11}
--------------------------

The proportions of subjects reaching above protective antibody level (i.e. ≥1.3 μg/mL) for serotype 6B increased after vaccination in RA without DMARD (*p* = 0.001) and controls (*p* \< 0.001) but not in RA with MTX and pSS without DMARD (Table [3](#Tab3){ref-type="table"}). For 23F, increases were found in RA without DMARD (*p* \< 0.001), pSS without DMARD (*p* = 0.05) and controls (*p* \< 0.001) but not in RA with MTX. The pre- to postvaccination percentage increase for serotype 6B and 23F respectively were 24% and 42% in RA without DMARD, 10% and 20% in RA with MTX, 14% and 26% in pSS without DMARD, and 28% and 40% in controls.Table 3ELISA IgG geometric mean concentrations and proportions of subjects reaching above putative protective antibody concentration (i.e. ≥1.3 μg/mL) before and after vaccination in treatment groups and controlsRA without DMARD\
(*n =* 50)RA with MTX\
(*n =* 10)pSS without DMARD (*n* = 15)Controls\
(*n =* 49)Geometric mean concentrations (μg/mL): 6B prevaccination (95% CI)0.6 (0.3--1.0)1.3 (0.5--2.9)0.6 (0.2--2.0)0.8 (0.5--1.3) 6B postvaccination (95% CI)3.4 (1.8--6.0)2.1 (0.8--5.6)2.3 (0.8--6.5)3.1 (1.9--5.0) *P* of increase\< 0.0010.050.05\< 0.001 23F prevaccination (95% CI)0.5 (0.3--0.8)1.0 (0.3--3.5)0.9 (0.4--1.9)0.6 (0.4--0.9) 23F postvaccination (95% CI)2.5 (1.5--4.1)1.7 (0.7--3.9)3.5 (1.1--11.5)3.3 (2.0--5.5)*P* of increase\< 0.0010.390.006\< 0.001Proportions of subjects with IgG concentration ≥ 1.3 μg/mL (%): 6B prevaccination (95% CI)38 (24--52)60 (23--97)33 (6--60)37 (23--51) 6B postvaccination (95% CI)62 (48--76)70 (35--100)47 (18--75)65 (51--79) *P* of increase0.0010.320.16\< 0.001 23F prevaccination (95% CI)26 (13--39)40 (3--77)47 (18--75)29 (15--42) 23F postvaccination (95% CI)68 (55--81)60 (23--97)73 (48--99)69 (56--83) *P* of increase\< 0.0010.160.046\< 0.001

Opsonophagocytic activity {#Sec12}
-------------------------

After vaccination, OPA increased in groups RA without DMARD (*p* \< 0.001), pSS without DMARD (*p* = 0.03) and controls (*p* \< 0.001) but did not change significantly in patients with RA on MTX. The mean percentage change in OPA was lower in RA on MTX (1.8%, *p* = 0.01), RA without DMARD (8.9%, *p* \< 0.01), but not in pSS without DMARD (10.5%), compared to controls (17.9%). Pre- and postvaccination OPA in patients with RA and pSS is shown in Fig. [2a and b](#Fig2){ref-type="fig"}, respectively. Positive correlations between percentage change in OPA and pre- to postvaccination increase in ELISA were found for patients with RA without DMARD (ρ = 0.28, *p* = 0.03) and controls (ρ = 0.45, *p* = 0.001).Fig. 2**a** Opsonophagocytic activity before and after PCV13 vaccination in RA and controls. **b** Opsonophagocytic activity before and after PCV13 vaccination in primary Sjögren's syndrome and controls

Effects of age and glucocorticoid treatment {#Sec13}
-------------------------------------------

Neither antibody response ratio nor pre- to postvaccination increase in ELISA correlated with age for all patients, subgroups, or controls. A negative correlation was found between percentage change in OPA and age in controls (ρ = − 0.36, *p* = 0.01) but not in patients. Prednisolone dose did not correlate with antibody response or percentage change in OPA.

Vaccine safety {#Sec14}
--------------

The vaccine was generally well tolerated, all reported side effects were considered mild-moderate and temporary (duration 1--2 days up to 1--2 weeks). The following side effects were reported in the group RA without DMARD: pain/skin reaction around injection site (*n* = 5), increased arthralgia (*n* = 3), upper respiratory tract symptoms (*n* = 2) and nausea (*n* = 1). In the group RA with MTX, 7 patients had low disease activity and 3 patients no activity (DAS28) at the time of vaccination. None of the patients reported increased disease activity or relapse after vaccination.

Discussion {#Sec15}
==========

This study demonstrated that pneumococcal conjugate vaccine was immunogenic in patients with RA and pSS syndrome without DMARD treatment, and the antibody response rates were comparable to those of healthy controls. In contrast, a small group of RA patients with MTX treatment had lower antibody responses compared to controls, in accordance with previous findings of our group \[[@CR8]\]. These results are in accordance with a meta-analysis of studies investigating immunogenicity of pneumococcal vaccine in RA finding that MTX treated patients with RA had decreased ability to respond to pneumococcal polysaccharide vaccine \[[@CR17]\]. Functionality of antibodies after vaccination, measured by an opsonophagocytosis assay, was lower in RA patients without DMARD compared to controls, and a weak positive correlation was found between OPA and ELISA in this group. However, we found a negative correlation between percentage change in OPA and age in controls, and the fact that controls were younger than RA patients could contribute to the difference in functional immune response. To the authors' knowledge, this is the first study of the immune response to pneumococcal conjugate vaccine in patients with RA and pSS without DMARD treatment. The underlying autoimmune pathologies of these diseases are well known to increase the risk of serious infections \[[@CR3], [@CR6], [@CR18]\], and pneumococcal vaccination is important to prevent invasive disease. Our findings, i.e. that pneumococcal conjugate vaccine was immunogenic in both RA and pSS without DMARD, support the use of this vaccination in newly diagnosed patients before starting immunosuppressive DMARD treatment.

Among the strengths of this study were the use of both ELISA and a functional antibody assay to evaluate the immune responses. No patients were lost to follow up.

Our study had some limitations. First, we only performed ELISA for two serotypes (6B and 23F). Although the serotypes are among the most common causes of IPD in our part of Sweden \[[@CR19]\], we cannot be certain that they are representative of the immune response to PCV13. At the same time, the studies on the immunogenicity of other pneumococcal serotypes prior to the licensure of the conjugate vaccine did not reveal any significant differences between serotypes and probably the impact of the rheumatic diseases or their treatment on antibody response would be similar for the other serotypes \[[@CR20]\]. Second, functionality of antibodies was evaluated with a phagocytic OPA assay to only one serotype (i.e. 23F), although validated previously \[[@CR15]\], it contrasts to the killing-type OPA assay which is now considered the standard method for vaccine evaluations \[[@CR21]\]. Further, small sample sizes may limit the generalizability of our results. Although the group of RA patients with MTX treatment (*n* = 10) arguably is too small for statistical analyses, the purpose of this group was merely to illustrate and confirm what previous studies have shown, i.e. that methotrexate decreases the antibody response to pneumococcal vaccination. The seemingly higher prevaccination antibody level of 6B in this group is probably a result of prior infections and it can explain the lower antibody response to this serotype. The fact that controls were younger than RA patients was considered a minor limitation, and it doesn't contradict our main findings, i.e. that antibody responses in patients with RA without DMARD were comparable to those of healthy controls.

In a recent study, adjuvanted H1N1 influenza vaccination of untreated pSS patients resulted in higher specific IgG titers compared to healthy controls, and autoantibody (Ro/SSA and La/SSB) titers increased. Endosomal toll-like receptor stimulated naïve B-cells in vitro were shown to differentiate and class switch more readily from untreated pSS patients compared with patients receiving hydroxychloroquine and healthy controls \[[@CR22]\]. However, in our study with pneumococcal vaccine, this enhanced antibody response could not be reproduced, which could possibly be due to the fact that not all pSS patients in the current study were anti-Ro/SSA and La/SSB seropositives.

Conclusions {#Sec16}
===========

Antigen challenge using pneumococcal conjugate vaccine in patients with RA or pSS without active anti-rheumatic treatment resulted in antibody response comparable to that of healthy controls. Similar to previous findings a decreased response to this vaccine was observed in RA patients treated with methotrexate.

These findings are in line with the previous recommendation that pneumococcal vaccination should be performed before initiation of MTX.
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